Best use of adjuvant systemic therapies II, chemotherapy aspects: dose of chemotherapy-cytotoxicity, duration and responsiveness (Q35601624)

9 August 2017

1 reference

title

Best use of adjuvant systemic therapies II, chemotherapy aspects: dose of chemotherapy-cytotoxicity, duration and responsiveness (English)

1 reference

9 August 2017

1 reference

1

Jonas Bergh

1 reference

9 August 2017

1 December 2003

1 reference

9 August 2017

1 reference

9 August 2017

12

1 reference

9 August 2017

6

1 reference

9 August 2017

529-537

1 reference

Long-term effects of mammography screening: updated overview of the Swedish randomised trials

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Where next with stem-cell-supported high-dose therapy for breast cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Dosing strategies for anticancer drugs: the good, the bad and body-surface area

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

High-dose therapy with autologous bone marrow stem cell support in primary and metastatic human breast cancer. A review

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Is there a role for intensive therapy in breast cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Dose-response effect of adjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Predicting the clinical status of human breast cancer by using gene expression profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Gene-Expression Profiles in Hereditary Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

A gene-expression signature as a predictor of survival in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900162-0

7 January 2021

10.1016/S0960-9776(03)00162-0

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14659131